We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00742352
Recruitment Status : Unknown
Verified August 2008 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : August 27, 2008
Last Update Posted : September 9, 2008
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center

Brief Summary:
The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.

Condition or disease
Atherosclerosis

Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : September 2008

Group/Cohort
Breast cancer patients
Lung cancer patients




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Breast cancer patients at the Tel-Aviv Sourasky Medical Center Lung cancer patients at the Tel-Aviv Sourasky Medical Center
Criteria

Inclusion Criteria:

  • Women over the age of 65 diagnosed with metastatic breast cancer
  • Men over the age of 65 diagnosed with lung cancer

Exclusion Criteria:

  • Patients under the age of 65
  • Patients diagnosed with chronic inflammatory disease or chronic infection
  • Patients taking steroids and NSAIDS on a regular basis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00742352


Contacts
Contact: Einat Even Sapir, MD PhD 972-3-6973532 evensap@tasmc.health.gov.il

Locations
Israel
Tel-Aviv Sourasky Medical Center Not yet recruiting
Tel Aviv, Israel, 64239
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center

Responsible Party: Prof. Einat Even-Sapir, Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier: NCT00742352     History of Changes
Other Study ID Numbers: TASMC-08-EES-253-CTIL
First Posted: August 27, 2008    Key Record Dates
Last Update Posted: September 9, 2008
Last Verified: August 2008

Additional relevant MeSH terms:
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases